Hong Kong firms favour mainland, South Asia for growth in snub to US, Europe: survey
Advertisement
They include EzyGreenPak, a year-old start-up offering environmentally friendly packaging products made of water-soluble and biodegradable non-woven fabrics, which is setting its sight on gaining new customers in Taiwan, Singapore and Malaysia, founder Wendy Lam said.
'Rising shipping and air transport costs, along with high tariff barriers, have prompted us to relegate the US and European Union markets in our priority list,' she said, adding that the firm had held an exhibition in Bangkok to gauge market conditions. 'These factors create disadvantages for our development goals.'
EzyGreenPak founder Wendy Lam. Photo: Handout
The pivot is supported by Hong Kong and Beijing's efforts to forge stronger ties with markets in Southeast Asia and the Middle East as US-China trade ties remain tense, after President Donald Trump launched his so-called reciprocal tariffs and the EU slapped punitive tariffs on China's electric vehicle exports.
Financial Secretary Paul Chan Mo-po held meetings with Hou Yanqi, China's top officials in Southeast Asia in January to boost bilateral trade and investment. Chan also led a delegation to the Middle East, laying the foundation for stronger financial market linkages.
One in four Hong Kong companies considered expanding into South Asia, according to HSBC, which surveyed 5,750 global firms in 13 markets from April 30 to May 12 about tariffs and international trade. Half of the Hong Kong respondents named mainland China as their top pick, while 23 per cent chose Europe, it said.
Advertisement
Nearly three-quarters of Hong Kong businesses said they were confident about growing their business globally over the next two years, the survey showed, despite Trump jacking up tariffs on Hong Kong exports to as high as 54 per cent in April.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
9 minutes ago
- South China Morning Post
China's cyberspace regulator summons Nvidia to explain H20 chip's alleged ‘back door' risks
China's cyberspace regulator has summoned Nvidia to explain the security risks related to the so-called 'back door safety' of its H20 chips, according to a statement on its website. The Cyberspace Administration of China said it has summoned and interviewed Nvidia over the tracking and remote control risks of its H20 chips and has requested the US company to explain and provide relevant proof regarding the issue. More to follow … Advertisement
South China Morning Post
9 minutes ago
- South China Morning Post
Wuxi AppTec raises US$981 mn in Hong Kong offer amid growing appetite for Chinese biotech
Wuxi AppTec , Asia's largest provider of contract pharmaceutical research, has raised HK$7.70 billion (US$981 million) through a sale of additional shares in Hong Kong as it rides the wave of bullish appetite for Chinese biotechnology shares. Advertisement The Shanghai-based company sold 73.8 million new shares to institutional investors at HK$104.27 each, a 6.9 per cent discount to their closing price of HK$112 on Wednesday, it said in a filing to Hong Kong's bourse on Thursday. The stock fell 5.2 per cent to HK$106.20 amid a declining market at 10.20am. The sale of additional shares, involving the issuance of stock equivalent to a 2.57 per cent stake in the company, was led by Morgan Stanley, Citi, Goldman Sachs and HSBC. 'The proceeds will provide readily available funding for the company to accelerate global expansion and capacity construction, serving as a driving force for its sustained long-term growth,' Wuxi AppTec said in a statement to the Hong Kong stock exchange. Wuxi AppTec's executives (L-R): Joint Company Secretary Yao Chi, Chairman Dr. Li Ge and Co-Chief Executive Officer Edward Hu during the company's IPO press conference on November 30, 2018. Photo: Edward Wong Wuxi AppTec is following the footsteps of other Chinese novel drug developers in tapping the capital markets for funds. Innovent Biologics raised HK$4.27 billion on July 4, Ascentage Pharma sold HK$1.49 billion of shares last week, while Shanghai Junshi Biosciences raised HK$1.04 million last month following Duality Biotherapeutics' HK$1.64 billion initial public offer in April. Advertisement Much of this bullishness has been driven by mainland investors buying shares in Hong Kong-listed Chinese biotech and pharmaceutical firms, according to Tony Ren, head of Asia healthcare research at Macquarie Capital.
South China Morning Post
an hour ago
- South China Morning Post
Why capital management and technology are key drivers of new business possibilities
02:58 How can companies build resilience and unlock growth in uncertain times? How can companies build resilience and unlock growth in uncertain times? Growing geopolitical uncertainties and sweeping trade policy changes have created an unpredictable global economic landscape. As new priorities evolve, how can companies navigate the world's increasingly complex business environment? Advertisement A global study titled 'New Realities, New Possibilities', which was conducted by DBS, a leading financial services group in Asia, and involved more than 800 chief financial officers (CFOs) and treasurers, found that 74 per cent of participants have made data-driven financial intelligence a priority. 'Improving data-driven financial intelligence can help enhance a firm's operational efficiency, which will allow it to make speedier decisions and help drive innovation,' Lim Soon Chong, group head of global transaction services at DBS, says. Lim and another DBS senior executive, Jolynn Wong, head of global transaction services at DBS Hong Kong, shared insights from the survey into how businesses can continue to thrive in the South China Morning Post's latest video-led InsiderTalk article. These regular InsiderTalk discussions focus on international business leaders and executives as they present opinions, strategies and future visions regarding their home markets and industries. Advertisement Lim and Wong explain why it is important for finance teams to be able to evolve and adapt their priorities to respond to today's complex, fast-changing business environment.
